ACAD
ACADIA PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$19.80
+3.56%Sep 29, 2026, 15:10 UTC
Acadia Pharmaceuticals received a patent allowance for Daybue that extends U.S. protection to March 2041.
Source:Sep 28, 2026, 20:05 UTC
The United States Patent and Trademark Office issued a Notice of Allowance for Acadia Pharmaceuticals' U.S. Patent Application No. 17/590,496 covering weight-banded dosing of trofinetide, extending U.S. patent protections to March 2041.
Source:Sep 25, 2026, 17:06 UTC
Acadia Pharmaceuticals reported that its Phase II Alzheimer's psychosis study narrowly missed its primary goal, though 60 mg results support continued Phase III development, sending its stock down 13%.
Source:Sep 24, 2026, 11:03 UTC
Acadia Pharmaceuticals reported that its drug remlifanserin failed to meet the primary endpoint in the ADP trial.
Aug 24, 2026, 07:01 UTC
The European Commission granted marketing authorization to Acadia Pharmaceuticals for DAYBU (trofinetide) as the first and only treatment for neurobehavioral symptoms of Rett syndrome in the European Union, for adults and pediatric patients aged five years and older.
Source:Aug 12, 2026, 19:04 UTC
ACADIA Pharmaceuticals outlined commercial expansion plans for its marketed therapies DAYBUE and NUPLAZID during a Canaccord Genuity-hosted discussion.
Source:Aug 4, 2026, 20:05 UTC
Acadia Pharmaceuticals reported its financial results for the second quarter ended June 30, 2026, with total revenue growing 17% year-over-year on an adjusted basis.
Jul 31, 2026, 00:00 UTC
Vistagen Therapeutics appointed Douglas J. Williamson, M.D. as a director, effective July 29, 2026, with stock option compensation and eligibility for the Director Compensation Plan.
Jun 26, 2026, 10:49 UTC
The CHMP of the EMA adopted a positive opinion recommending marketing authorization for DAYBU (trofinetide) for Rett syndrome in the EU.